Finanzas de Black Diamond Therapeutics Inc (BDTX)BDTXBlack Diamond Therapeutics Inc

Evaluating the bottom line, Black Diamond Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -37.21%, provide a clear picture of how effectively BDTX converts its operational activities into shareholder value.

In the context of the broader market, BDTX competes directly with industry leaders such as UNCY and PMVP. With a market capitalization of $95.37M, it holds a significant position in the sector. When comparing efficiency, BDTX's gross margin of N/A stands against UNCY's N/A and PMVP's N/A. Such benchmarking helps identify whether Black Diamond Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported total revenue of $70 million in Q1 2025, with a gross margin of 100% during the same period, indicating strong potential for profitability if the company can sustain revenue generation.